SecBot SecBot
EFFECT ·Filed Sep 9, 2026

EDIT

Editas Medicine, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed1mo ago SEC9999999995-26-002915
IPO/offering going effective
Actionable Insight • Neutral

Monitor for any subsequent prospectus supplement or takedown announcement that would signal actual capital raise and dilution. The shelf being effective is a procedural step — the real market impact depends on whether and when Editas draws on it.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d
EDIT ▼ -0.72% at T+20d
NEUTRAL call -0.72% · α vs SPY -2.92% · entry $2.77 → $2.75
Next anchor: T+60d in 5w
Latest observation: T+32 -17.18% FF3 residual α
Entry = T+0 close
Sep 9, 2026
via day close
T+1d
-4.33%
call -4.33% · α -3.73%
$2.65
settled 7w ago
T+5d
-2.53%
call -2.53% · α -2.19%
$2.70
settled 6w ago
T+20d
-0.72%
call -0.72% · α -2.92%
$2.75
settled 20d ago
T+60d
Pending
in 5w

Price Chart

Loading chart...

Executive Summary

Editas Medicine's S-3 shelf registration (File No. 333-298665) became effective on September 8, 2026. This allows the company to offer and sell securities, including common stock, preferred stock, debt securities, warrants, and units, from time to time at its discretion. The effectiveness creates a potential dilution overhang for common stockholders, as the company can now tap the market for capital without further SEC clearance.

Key Facts

  • S-3 shelf registration became effective on 2026-09-08.
  • File Number: 333-298665.
  • Company can now sell various securities (common stock, preferred, debt, warrants, units) at its discretion.
  • No specific offering size, pricing, or timing disclosed in the EFFECT notice.
  • Market cap: ~$465M; 67% analyst bullish consensus.
  • Institutional 13F top holders: BlackRock $34M, Ra Capital $29M, Vanguard $20M; recent net accumulation (9 adds, 6 doubled).

Financial Impact

Undisclosed — shelf registration effective; no offering amount or terms specified.

dilutioncapital structure

Risk Factors

  • Potential dilution if company sells common stock under the shelf.
  • Overhang may pressure stock price even without immediate offering.
  • No specific use of proceeds disclosed, creating uncertainty.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002915
Document: 9999999995-26-002915-index.html9999999995-26-002915
Document: 9999999995-26-002915.txt9999999995-26-002915
16 reports for EDIT
Performance horizon
60% Hit rate @ T+20 6 of 10 directional calls Went positive at some point 9 of 11 best @ T+20▲ +23.25%May 26, 2026
Filters
Rows
Reports for EDIT — sortable, filterable
TypeNow
Oct 8, 2026
18d ago
8-K
BULLISH ★ 6/10
$2.84awaiting T+20—$2.40 (−15.49%)
Sep 9, 2026
6w ago
EFFECT
NEUTRAL ★ 4/10
$2.77 $2.75▼ −0.72%▼ −2.92%$2.40 (−13.36%)
Jun 11, 2026
19w ago
Institutional Cluster
MIXED ★ 5/10
$2.44 $3.30▲ +35.25%▲ +33.35%$2.40 (−1.64%)
May 26, 2026
21w ago
424B5
BEARISH ★ 7/10
$3.57 $2.74▲ +23.25%▲ +21.35%$2.40 (+32.77%)
May 26, 2026
21w ago
8-K
BEARISH ★ 7/10
$3.57 $2.74▲ +23.25%▲ +21.35%$2.40 (+32.77%)
May 26, 2026
21w ago
Press Release
BEARISH ★ 8/10
$3.08 $2.83▲ +8.12%▲ +6.17%$2.40 (+22.08%)
May 26, 2026
21w ago
8-K
BULLISH ★ 5/10
$3.08 $2.83▼ −8.12%▼ −6.17%$2.40 (−22.08%)
May 26, 2026
21w ago
424B5
BEARISH ★ 7/10
$3.08 $2.83▲ +8.12%▲ +6.17%$2.40 (+22.08%)
May 26, 2026
21w ago
Press Release
BEARISH ★ 6/10
$3.08 $2.83▲ +8.12%▲ +6.17%$2.40 (+22.08%)
May 26, 2026
21w ago
Press Release
BULLISH ★ 7/10
$3.08 $2.83▼ −8.12%▼ −6.17%$2.40 (−22.08%)
Showing 10 of 16

US Market Status

Market Closed — Opens in 8h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026